KOL Perspectives: Rituximab Use in Lupus
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Questions topics:
› Current & future use of RTX in lupus
› Views on RTX’s Phase II/III EXPLORER trial re-analysis
› Opinion on data demonstrating that RTX is effective for the management of refractory SLE
› Views on data from the Phase II SYNBIoSe study assessing RTX + BEL combination therapy
› Lupus patients most suitable for RTX + BEL combination therapy
› Use of RTX + BEL combination therapy
Scope
› The insight briefing is based on Sociable Pharma’s analysis of primary research with our Lupus key opinion leaders (KOLs)
› In total, we conducted interviews with 10 KOLs:
– 5 Europe-based & 5 N. America-based
– Interviews performed during Q2 2018
> KOL data is analyzed to produce:
– Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma's analysts
Key Highlights
Most US KOLs stated that future launch of biosimilar RTX will have no impact on their overall use of RTX, but uptake will depend on price
Most KOLs highlighted that the level of background medication used in the EXPLORER trial was too high and consequently impeded results
Most KOLs flagged that payers may be a barrier to combination therapy use, especially given the lack of approval for RTX in lupus
Reasons to Buy
Combines Qualitative & semi-quantitative insight from key opinion leaders on Rituximab Use in Lupus
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
GSK
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Immunology reports

